SCHEMBL4885779

SCHEMBL4885779

CCCC(O)OC(=O)c1ccc(C(=O)OC(O)CCC)c(C(=O)OC(O)CCC)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.50
TSHR P16473 1/20 0.50
MAPK1 P28482 1/20 0.50
PRKCA P17252 2/20 0.39
PRKCD Q05655 2/20 0.39
CA12 O43570 4/20 0.38
CA1 P00915 4/20 0.38
CA2 P00918 4/20 0.38
CA7 P43166 4/20 0.38
CA9 Q16790 4/20 0.38
CA14 Q9ULX7 4/20 0.38
KDM4E B2RXH2 6/20 0.37
KMT2A Q03164 2/20 0.37
TAS1R3 Q7RTX0 3/20 0.36
TAS1R1 Q7RTX1 3/20 0.36
LMNA P02545 2/20 0.36
PTPN1 P18031 1/20 0.36
HPGD P15428 3/20 0.35
MAPT P10636 2/20 0.35
GLA P06280 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2128862 0.87 ALDH1A1 (0.49) ALDH1A1TSHRMAPK1PRKCAPRKCD
SCHEMBL4885782 0.87 ALDH1A1 (0.43) ALDH1A1TSHRMAPK1KDM4EKMT2A
SCHEMBL128505 0.85 CA12 (0.46) ALDH1A1TSHRMAPK1PRKCAPRKCD
SCHEMBL3074456 0.82 PRKCA (0.45) ALDH1A1PRKCAPRKCDTAS1R3TAS1R1
SCHEMBL1513875 0.82 ALDH1A1 (0.52) ALDH1A1TSHRMAPK1CA2KDM4E
SCHEMBL2061233 0.79 MAPT (0.49) ALDH1A1TSHRMAPK1CA12CA1
Terephthalic Acid SCHEMBL8439001 0.79 MAPT (0.49) ALDH1A1TSHRMAPK1CA12CA1
SCHEMBL13218959 0.79 SLC6A2 (0.51) ALDH1A1TSHRCA12CA1CA2
SCHEMBL435764 0.78 ALDH1A1 (0.53) ALDH1A1TSHRMAPK1PRKCAPRKCD
SCHEMBL29808730 0.78 ALDH1A1 (0.53) ALDH1A1TSHRMAPK1PRKCAPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220211725-A1 Pharmaceutical Composition Comprising Venetoclax ALEMBIC PHARMACEUTICALS LIMITED (IN) 2022-07-07 US claimed
WO-2020225738-A1 PHARMACEUTICAL COMPOSITION COMPRISING VENETOCLAX ALEMBIC PHARMACEUTICALS LIMITED (IN) 2020-11-12 WO claimed
EP-1847257-B1 Solid preparation comprising enteric solid dispersion SHINETSU CHEMICAL CO (JP) 2017-11-22 EP claimed
US-20140370091-A1 Method for Producing Aqueous Enteric Coating Liquid, Solid Preparation, and Method for Producing Same SHIN-ETSU CHEMICAL CO., LTD. (JP) 2014-12-18 US claimed
EP-2813218-A1 Method for producing aqueous enteric coating liquid, solid preparation, and method for producing same Shin-Etsu Chemical Co., Ltd. (JP) 2014-12-17 EP claimed
US-20080038340-A1 Solid dosage form of enteric solid dispersion and method for producing the same SHIN-ETSU CHEMICAL CO., LTD. 2008-02-14 US claimed
EP-1886673-A2 Solid dosage form of enteric solid dispersion and method for producing the same Shin-Etsu Chemical Co., Ltd. (JP) 2008-02-13 EP claimed
US-20070248682-A1 SOLID PREPARATION COMPRISING ENTERIC SOLID DISPERSION SHIN-ETSU CHEMICAL CO., LTD. (JP) 2007-10-25 US claimed
EP-1847257-A2 Solid preparation comprising enteric solid dispersion Shin-Etsu Chemical Co., Ltd. (JP) 2007-10-24 EP claimed
US-20250242031-A1 POLYMER SALTS FOR IMPROVED DRUG DELIVERY FROM AMORPHOUS SOLID DISPERSIONS PURDUE RESEARCH FOUNDATION 2025-07-31 US disclosed
EP-4479092-A1 POLYMER SALTS FOR IMPROVED DRUG DELIVERY FROM AMORPHOUS SOLID DISPERSIONS Purdue Research Foundation (US) 2024-12-25 EP disclosed
WO-2023154171-A1 POLYMER SALTS FOR IMPROVED DRUG DELIVERY FROM AMORPHOUS SOLID DISPERSIONS PURDUE RESEARCH FOUNDATION (US) 2023-08-17 WO disclosed
US-20220211725-A1 Pharmaceutical Composition Comprising Venetoclax ALEMBIC PHARMACEUTICALS LIMITED (IN) 2022-07-07 US disclosed
US-11292793-B2 Solid dispersions of amorphous Lumateperone p-Tosylate DR. REDDY'S LABORATORIES LIMITED (IN) 2022-04-05 US disclosed
US-20080038340-A1 Solid dosage form of enteric solid dispersion and method for producing the same SHIN-ETSU CHEMICAL CO., LTD. 2008-02-14 US disclosed
EP-1886673-A2 Solid dosage form of enteric solid dispersion and method for producing the same Shin-Etsu Chemical Co., Ltd. (JP) 2008-02-13 EP disclosed
US-20070248682-A1 SOLID PREPARATION COMPRISING ENTERIC SOLID DISPERSION SHIN-ETSU CHEMICAL CO., LTD. (JP) 2007-10-25 US disclosed
EP-1847257-A2 Solid preparation comprising enteric solid dispersion Shin-Etsu Chemical Co., Ltd. (JP) 2007-10-24 EP disclosed
US-20070196399-A1 ENTERIC-COATED PREPARATION COVERED WITH ENTERIC COATING MATERIAL FOR SITE-SPECIFIC DELIVERY OF DRUG TO SITE WITHIN THE SMALL INTESTINE SHIN-ETSU CHEMICAL CO., LTD. (JP) 2007-08-23 US disclosed
EP-1820498-A2 Enteric-coated preparation for site-specific delivery of drug to site within the small intestine Shin-Etsu Chemical Co., Ltd. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11292793-B2 Solid dispersions of amorphous Lumateperone p-Tosylate HTR2A, HTR2C, HTR1A ALDH1A1 2652/4885TSHR 100/4885MAPK1 4061/4885
US-20250242031-A1 POLYMER SALTS FOR IMPROVED DRUG DELIVERY FROM AMORPHOUS SOLID DISPERSIONS SRI, SYNGR2, PSD ALDH1A1 3898/4885TSHR 4586/4885MAPK1 1802/4885
US-20220211725-A1 Pharmaceutical Composition Comprising Venetoclax U2AF1, SF3B1, SF3B3 ALDH1A1 3436/4885TSHR 4796/4885MAPK1 3091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.